|
Fri, 10/31/2025 - 16:52 |
Light-based tool continuously monitors vaccine quality during production |
Purdue |
|
Sat, 09/20/2025 - 15:27 |
Merck Receives Positive EU CHMP Opinion for ENFLONSIA (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season |
Merck |
|
Tue, 07/15/2025 - 14:39 |
Merck to Initiate Phase 3 Trials for Investigational Once-Monthly HIV Prevention Pill |
Merck |
|
Wed, 07/02/2025 - 02:07 |
Merck to Hold Second-Quarter 2025 Sales and Earnings Conference Call |
Merck |
|
Thu, 05/08/2025 - 16:31 |
Merck Animal Health and State of Kansas Announce $895 Million Investment in Manufacturing and Research & Development Facilities in De Soto |
Merck |
|
Tue, 04/01/2025 - 18:18 |
Merck to Hold First-Quarter 2025 Sales and Earnings Conference Call |
Merck |
|
Thu, 06/27/2024 - 22:46 |
Verizon elects Caroline A. Litchfield to its board of directors |
Verizon Communi... |
|
Tue, 02/05/2019 - 15:44 |
FDA Accepts for Review New Drug Application (NDA) for Mercks Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA (Ceftolozane and Tazobactam) |
Merck |
|
Wed, 12/26/2018 - 04:36 |
FDA Approves VAXELIS, Sanofi and Mercks Pediatric Hexavalent Combination Vaccine |
Sanofi |
|
Thu, 12/20/2018 - 04:33 |
Lynparza meets primary endpoint in Phase III SOLO-3 trial for the treatment of relapsed BRCA-mutated advanced ovarian cancer |
AstraZeneca |
|
Thu, 12/20/2018 - 03:42 |
LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:35 |
LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:08 |
Lynparza approved by US FDA for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer |
AstraZeneca |
|
Fri, 12/14/2018 - 08:02 |
Merck to Acquire Privately Held Antelliq Group |
Merck |
|
Wed, 12/12/2018 - 14:38 |
Merck and Instituto Butantan Announce Collaboration Agreement to Develop Vaccines to Protect Against Dengue Infections |
Merck |
|
Tue, 12/11/2018 - 13:20 |
Results of triple combination arm of BL-8040, KEYTRUDA and chemotherapy expected in H2 2019 |
Biolinerx |
|
Mon, 12/10/2018 - 01:21 |
Mercks President of Global Human Health Adam H. Schechter to Leave Merck Frank Clyburn Named Chief Commercial Officer and Michael Nally Named Chief Marketing Officer |
Cubist Pharmace... |
|
Mon, 12/03/2018 - 07:31 |
FDA grants breakthrough device designation to artificial intelligence software for CTEPH pattern recognition from Bayer and MSD |
bayer |
|
Wed, 11/28/2018 - 17:56 |
Approvals Based on Findings from the Pivotal Phase 3 DRIVE-AHEAD and DRIVE-FORWARD Trials Evaluating the Efficacy and Safety of DELSTRIGO and PIFELTRO Through 96 Weeks |
Merck |
|
Tue, 11/13/2018 - 14:50 |
Merck Begins Rolling Submission of Licensure Application for V920 (rVSVG-ZEBOV-GP) to U.S. Food and Drug Administration |
Merck |
|
Mon, 11/12/2018 - 06:07 |
FDA Accepts Regulatory Submission for LYNPARZA (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review |
Merck |
|
Mon, 11/12/2018 - 03:01 |
US FDA accepts regulatory submission for Lynparza maintenance therapy in newly-diagnosed, BRCA-mutated advanced ovarian cancer and grants Priority Review |
AstraZeneca |
|
Fri, 11/09/2018 - 05:02 |
First presentation of LENVIMA and KEYTRUDA combination data in patients with metastatic non-small cell lung cancer, metastatic melanoma and metastatic urothelial carcinoma from Study 111/KEYNOTE-146 |
EISAI |
|
Tue, 11/06/2018 - 21:29 |
OncoSec Doses First Patient in KEYNOTE-890 Phase 2 Clinical Trial |
OncoSec Medical |
|
Thu, 10/25/2018 - 09:13 |
Merck Announces Increased Fourth-Quarter Dividend and $10 Billion Share Repurchase Authorization |
Merck |
